Latest Alseres Pharmaceutcl (ALSE) Headlines
Post# of 6
Posted On: 03/08/2014 6:41:44 PM
Latest Alseres Pharmaceutcl (ALSE) Headlines
Concise Analysis of the International Radiopharmaceuticals Market
M2 - Fri Feb 14, 5:11AM CST
Research and Markets (http://www.researchandmarkets.com/research/5ltj8g/radiopharmaceutica) has announced the addition of the "Concise Analysis of the International Radiopharmaceuticals Market" report to their offering. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Middle East, and Latin America. Annual estimates and forecasts are provided for the period 2010 through 2018. Also, a six-year historic analysis is provided for these markets. This report analyzes the worldwide markets for Radiopharmaceuticals in US$ Million by the following Product Segments: - Diagnostic Radiopharmaceuticals - Therapeutic Radiopharmaceuticals. The report profiles 69 companies including many key and niche players such as: - Actinium Pharmaceuticals Inc. - Advanced Medical Isotope Corporation - Alseres Pharmaceuticals Inc. - Bayer HealthCare Pharmaceuticals - Bracco Diagnostics Inc. - Cardinal Health Inc. - Covidien Plc - Eli Lilly and Company - Erigal Limited - EUSA Pharma (Europe) Ltd. - GE Healthcare - IBA Group - Immunomedics Inc. - Jubilant Life Sciences Limited - Lantheus Medical Imaging Inc. - Medi-Radiopharma Ltd. - Nordion Inc. - Peregrine Pharmaceuticals Inc. - PETNET Solutions Inc. - Positron Corporation - Singapore Radiopharmaceuticals Pte Ltd. - Triad Isotopes Inc. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. For information on site licence pricing please click on Enquire before buying. Key Topics Covered: I. Introduction, Methodology & Product Definitions II. Executive Summary 1. Industry Overview 2. Growth Drivers & Trends 3. Market Challenges 4. Therapeutic Radiopharmaceutical Products Under Development 5. Imaging Agents - An Overview 6. Nuclear Medicine - An Overview 7. Product Overview 8. Product Innovations/Introductions 9. Product Innovations/Introductions In Recent Past- A Perspective Builder 10. Recent Industry Activity 11. Corporate Activity In The Recent Past - A Perspective Builder 12. Focus On Select Players 13. Global Market Perspective III. Market 1. The United States 2. Canada 3. Japan 4. Europe 5. Asia-Pacific 6. Middle East 7. Latin America IV. Competitive Landscape Total Companies Profiled: 69 (including Divisions/Subsidiaries - 79) - The United States (36) - Canada (2) - Japan (1) - Europe (28) - France (2) - Germany (2) - The United Kingdom (4) - Italy (2) - Spain (1) - Rest of Europe (17) - Asia-Pacific (Excluding Japan) (9) - Latin America (1) - Africa (1) - Middle East (1) For more information visit http://www.researchandmarkets.com/research/5l...rmaceutica
Nova Scotia Power approves preferred share dividend of CAD0.37
M2 - Thu Feb 06, 5:21AM CST
The board of directors of an electric utility company, Nova Scotia Power Inc (TSX:NSI.PR.D), based in Canada, authorised a quarterly dividend of CAD0.37 per share on its series D first preferred share, the company declared on Wednesday.
Nova Scotia Power Inc. Approves Preferred ShareQuarterly Dividend
Business Wire - Wed Feb 05, 2:14PM CST
On February 5, 2014 the Board of Directors of Nova Scotia Power Inc. (TSX: NSI.PR.D) approved a quarterly dividend of $0.36875 per Nova Scotia Power Incorporated Series D First Preferred Share payable on and after April 15, 2014 to Series D preferred shareholders of record April 1, 2014.
Navidea Biopharmaceuticals Announces Issuance of New U.S. Patent Covering Formulation for Neuroimaging Agent, NAV5001
Business Wire - Thu Nov 14, 7:30AM CST
Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that the U.S. Patent and Trademark Office (USPTO) has issued a new patent covering the formulation of the Company's radiolabeled dopamine transporter (DAT) receptor ligand, NAV5001, used with SPECT imaging for potential differential diagnosis of Parkinsonian Syndromes and Dementia with Lewy Bodies. The patent (8,574,545) is set to expire in 2031.
Nova Scotia Power declares preferred dividend of USD0.36875 per share for Q4
M2 - Thu Nov 07, 3:33AM CST
The board of directors of Nova Scotia Power Inc (TSX:NSI.PR.D) that provides electricity generation, transmission and distribution services, authorised a series D first preferred stock dividend of USD0.36875 per share for the fourth quarter, the company declared on Wednesday.
Global Strategic Business Radiopharmaceuticals Report 2013-2018: High Costs of Drug Development Piques Manufacturers
M2 - Fri Aug 02, 9:34AM CDT
Research and Markets (http://www.researchandmarkets.com/research/xckkfp/radiopharmaceutica#summary) has announced the addition of the "Radiopharmaceuticals - Global Strategic Business Report" report to their offering. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Middle East, and Latin America. Annual estimates and forecasts are provided for the period 2010 through 2018. Also, a six-year historic analysis is provided for these markets. This report analyzes the worldwide markets for Radiopharmaceuticals in US$ Million by the following Product Segments: - Diagnostic Radiopharmaceuticals - Therapeutic Radiopharmaceuticals. The report profiles 69 companies including many key and niche players such as: - Actinium Pharmaceuticals Inc. - Advanced Medical Isotope Corporation - Alseres Pharmaceuticals Inc. - Bayer HealthCare Pharmaceuticals - Bracco Diagnostics Inc. - Cardinal Health Inc. - Covidien Plc - Eli Lilly and Company - Erigal Limited - EUSA Pharma (Europe) Ltd. - GE Healthcare - IBA Group - Immunomedics Inc. - Jubilant Life Sciences Limited - Lantheus Medical Imaging Inc. - Medi-Radiopharma Ltd. - Nordion Inc. - Peregrine Pharmaceuticals Inc. - PETNET Solutions Inc. - Positron Corporation - Singapore Radiopharmaceuticals Pte Ltd. - Triad Isotopes Inc. Key Topics Covered: Click the link below to view the full extended table of contents and list of companies featured. I. Introduction, Methodology & Product Definitions II. Executive Summary 1. Industry Overview 2. Growth Drivers & Trends 3. Market Challenges 4. Therapeutic Radiopharmaceutical Products Under Development 5. Imaging Agents - An Overview 6. Nuclear Medicine - An Overview 7. Product Overview 8. Product Innovations/Introductions 9. Product Innovations/Introductions In Recent Past- A Perspective Builder 10. Recent Industry Activity 11. Corporate Activity In The Recent Past - A Perspective Builder 12. Focus On Select Players 13. Global Market Perspective III. Market 1. The United States 2. Canada 3. Japan 4. Europe 5. Asia-Pacific 6. Middle East 7. Latin America IV. Competitive Landscape Total Companies Profiled: 69 (including Divisions/Subsidiaries - 79) - The United States (36) - Canada (2) - Japan (1) - Europe (28) - - France (2) - - Germany (2) - - The United Kingdom (4) - - Italy (2) - - Spain (1) - - Rest of Europe (17) - Asia-Pacific (Excluding Japan) (9) - Latin America (1) - Africa (1) - Middle East (1) For more information visit http://www.researchandmarkets.com/research/xc...ca#summary
Nova Scotia Power Inc. Issues $300 Million ofMedium Term Notes
Business Wire - Fri Jul 19, 8:59AM CDT
Today, Nova Scotia Power Inc. completed the issue of $300 million Series Z Medium Term Notes. The Series Z Notes bear interest at the rate of 4.50% and yield 4.537% per annum until July 20, 2043.
Nova Scotia Power's board approves USD0.36875 quarterly preferred share dividend
M2 - Mon Jul 08, 4:26AM CDT
The board of directors of Nova Scotia Power Inc (TSX:NSI.PR.D) on Friday announced the approval of quarterly dividend of USD0.36875 per Nova Scotia Power Incorporated Series D first preferred share.
Nova Scotia Power announces quarterly dividend of USD0.36875 per share on its preferred stock
M2 - Mon Jul 08, 3:06AM CDT
The board of directors of Nova Scotia Power Inc (TSX:NSI.PR.D), a provider of electricity generation, transmission and distribution services, authorised series D first preferred stock dividends of USD0.36875 per share, the company declared on Friday.
Nova Scotia Power announces series D preferred dividend of USD0.36875 per share
M2 - Thu Feb 07, 4:36AM CST
The board of directors of Nova Scotia Power Inc (TSX:NSI.PR.D), an electricity provider, has authorised a series D first preferred dividend of USD0.36875 per share for the quarter ending 31 March 2013, the company declared on Wednesday.
Concise Analysis of the International Radiopharmaceuticals Market
M2 - Fri Feb 14, 5:11AM CST
Research and Markets (http://www.researchandmarkets.com/research/5ltj8g/radiopharmaceutica) has announced the addition of the "Concise Analysis of the International Radiopharmaceuticals Market" report to their offering. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Middle East, and Latin America. Annual estimates and forecasts are provided for the period 2010 through 2018. Also, a six-year historic analysis is provided for these markets. This report analyzes the worldwide markets for Radiopharmaceuticals in US$ Million by the following Product Segments: - Diagnostic Radiopharmaceuticals - Therapeutic Radiopharmaceuticals. The report profiles 69 companies including many key and niche players such as: - Actinium Pharmaceuticals Inc. - Advanced Medical Isotope Corporation - Alseres Pharmaceuticals Inc. - Bayer HealthCare Pharmaceuticals - Bracco Diagnostics Inc. - Cardinal Health Inc. - Covidien Plc - Eli Lilly and Company - Erigal Limited - EUSA Pharma (Europe) Ltd. - GE Healthcare - IBA Group - Immunomedics Inc. - Jubilant Life Sciences Limited - Lantheus Medical Imaging Inc. - Medi-Radiopharma Ltd. - Nordion Inc. - Peregrine Pharmaceuticals Inc. - PETNET Solutions Inc. - Positron Corporation - Singapore Radiopharmaceuticals Pte Ltd. - Triad Isotopes Inc. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. For information on site licence pricing please click on Enquire before buying. Key Topics Covered: I. Introduction, Methodology & Product Definitions II. Executive Summary 1. Industry Overview 2. Growth Drivers & Trends 3. Market Challenges 4. Therapeutic Radiopharmaceutical Products Under Development 5. Imaging Agents - An Overview 6. Nuclear Medicine - An Overview 7. Product Overview 8. Product Innovations/Introductions 9. Product Innovations/Introductions In Recent Past- A Perspective Builder 10. Recent Industry Activity 11. Corporate Activity In The Recent Past - A Perspective Builder 12. Focus On Select Players 13. Global Market Perspective III. Market 1. The United States 2. Canada 3. Japan 4. Europe 5. Asia-Pacific 6. Middle East 7. Latin America IV. Competitive Landscape Total Companies Profiled: 69 (including Divisions/Subsidiaries - 79) - The United States (36) - Canada (2) - Japan (1) - Europe (28) - France (2) - Germany (2) - The United Kingdom (4) - Italy (2) - Spain (1) - Rest of Europe (17) - Asia-Pacific (Excluding Japan) (9) - Latin America (1) - Africa (1) - Middle East (1) For more information visit http://www.researchandmarkets.com/research/5l...rmaceutica
Nova Scotia Power approves preferred share dividend of CAD0.37
M2 - Thu Feb 06, 5:21AM CST
The board of directors of an electric utility company, Nova Scotia Power Inc (TSX:NSI.PR.D), based in Canada, authorised a quarterly dividend of CAD0.37 per share on its series D first preferred share, the company declared on Wednesday.
Nova Scotia Power Inc. Approves Preferred ShareQuarterly Dividend
Business Wire - Wed Feb 05, 2:14PM CST
On February 5, 2014 the Board of Directors of Nova Scotia Power Inc. (TSX: NSI.PR.D) approved a quarterly dividend of $0.36875 per Nova Scotia Power Incorporated Series D First Preferred Share payable on and after April 15, 2014 to Series D preferred shareholders of record April 1, 2014.
Navidea Biopharmaceuticals Announces Issuance of New U.S. Patent Covering Formulation for Neuroimaging Agent, NAV5001
Business Wire - Thu Nov 14, 7:30AM CST
Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that the U.S. Patent and Trademark Office (USPTO) has issued a new patent covering the formulation of the Company's radiolabeled dopamine transporter (DAT) receptor ligand, NAV5001, used with SPECT imaging for potential differential diagnosis of Parkinsonian Syndromes and Dementia with Lewy Bodies. The patent (8,574,545) is set to expire in 2031.
Nova Scotia Power declares preferred dividend of USD0.36875 per share for Q4
M2 - Thu Nov 07, 3:33AM CST
The board of directors of Nova Scotia Power Inc (TSX:NSI.PR.D) that provides electricity generation, transmission and distribution services, authorised a series D first preferred stock dividend of USD0.36875 per share for the fourth quarter, the company declared on Wednesday.
Global Strategic Business Radiopharmaceuticals Report 2013-2018: High Costs of Drug Development Piques Manufacturers
M2 - Fri Aug 02, 9:34AM CDT
Research and Markets (http://www.researchandmarkets.com/research/xckkfp/radiopharmaceutica#summary) has announced the addition of the "Radiopharmaceuticals - Global Strategic Business Report" report to their offering. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Middle East, and Latin America. Annual estimates and forecasts are provided for the period 2010 through 2018. Also, a six-year historic analysis is provided for these markets. This report analyzes the worldwide markets for Radiopharmaceuticals in US$ Million by the following Product Segments: - Diagnostic Radiopharmaceuticals - Therapeutic Radiopharmaceuticals. The report profiles 69 companies including many key and niche players such as: - Actinium Pharmaceuticals Inc. - Advanced Medical Isotope Corporation - Alseres Pharmaceuticals Inc. - Bayer HealthCare Pharmaceuticals - Bracco Diagnostics Inc. - Cardinal Health Inc. - Covidien Plc - Eli Lilly and Company - Erigal Limited - EUSA Pharma (Europe) Ltd. - GE Healthcare - IBA Group - Immunomedics Inc. - Jubilant Life Sciences Limited - Lantheus Medical Imaging Inc. - Medi-Radiopharma Ltd. - Nordion Inc. - Peregrine Pharmaceuticals Inc. - PETNET Solutions Inc. - Positron Corporation - Singapore Radiopharmaceuticals Pte Ltd. - Triad Isotopes Inc. Key Topics Covered: Click the link below to view the full extended table of contents and list of companies featured. I. Introduction, Methodology & Product Definitions II. Executive Summary 1. Industry Overview 2. Growth Drivers & Trends 3. Market Challenges 4. Therapeutic Radiopharmaceutical Products Under Development 5. Imaging Agents - An Overview 6. Nuclear Medicine - An Overview 7. Product Overview 8. Product Innovations/Introductions 9. Product Innovations/Introductions In Recent Past- A Perspective Builder 10. Recent Industry Activity 11. Corporate Activity In The Recent Past - A Perspective Builder 12. Focus On Select Players 13. Global Market Perspective III. Market 1. The United States 2. Canada 3. Japan 4. Europe 5. Asia-Pacific 6. Middle East 7. Latin America IV. Competitive Landscape Total Companies Profiled: 69 (including Divisions/Subsidiaries - 79) - The United States (36) - Canada (2) - Japan (1) - Europe (28) - - France (2) - - Germany (2) - - The United Kingdom (4) - - Italy (2) - - Spain (1) - - Rest of Europe (17) - Asia-Pacific (Excluding Japan) (9) - Latin America (1) - Africa (1) - Middle East (1) For more information visit http://www.researchandmarkets.com/research/xc...ca#summary
Nova Scotia Power Inc. Issues $300 Million ofMedium Term Notes
Business Wire - Fri Jul 19, 8:59AM CDT
Today, Nova Scotia Power Inc. completed the issue of $300 million Series Z Medium Term Notes. The Series Z Notes bear interest at the rate of 4.50% and yield 4.537% per annum until July 20, 2043.
Nova Scotia Power's board approves USD0.36875 quarterly preferred share dividend
M2 - Mon Jul 08, 4:26AM CDT
The board of directors of Nova Scotia Power Inc (TSX:NSI.PR.D) on Friday announced the approval of quarterly dividend of USD0.36875 per Nova Scotia Power Incorporated Series D first preferred share.
Nova Scotia Power announces quarterly dividend of USD0.36875 per share on its preferred stock
M2 - Mon Jul 08, 3:06AM CDT
The board of directors of Nova Scotia Power Inc (TSX:NSI.PR.D), a provider of electricity generation, transmission and distribution services, authorised series D first preferred stock dividends of USD0.36875 per share, the company declared on Friday.
Nova Scotia Power announces series D preferred dividend of USD0.36875 per share
M2 - Thu Feb 07, 4:36AM CST
The board of directors of Nova Scotia Power Inc (TSX:NSI.PR.D), an electricity provider, has authorised a series D first preferred dividend of USD0.36875 per share for the quarter ending 31 March 2013, the company declared on Wednesday.
(0)
(0)